

Supporting Information

Membrane Active Vancomycin Analogues: A Strategy to Combat Bacterial Resistance

Venkateswarlu Yarlagadda, Padma Akkapeddi, Goutham B. Manjunath and Jayanta Halder*

Chemical Biology and Medicinal Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bengaluru 560064, Karnataka, India.

*Corresponding Author: jayanta@jncasr.ac.in, Telephone: +91-80-2208-2565, Fax: +91-80-2208-2627

Table of Contents


Page S2: Supplementary schemes

Page S3-S8: Supplementary figures and Tables


Page S9-S33: Characterization (HPLC chromatograms, NMR and Mass spectra of vancomycin and new vancomycin analogues)

I. Supplementary schemes

Scheme S1: Synthesis of 3-(tetradecylamino)propyl-vancomycin carboxamide (control compound, **13**).



Scheme S2: Synthesis of lipophilic cationic segment (control compound, **14**).



II. Supplementary figures and Tables




Figure S1

Antibacterial activity comparison of control compounds (**13** and **14**) with compound **6**. (A) Antibacterial activity of compounds **13** and **6** against VRE; vancomycin-resistant *E. faecium* (B) Antibacterial activity of compounds **14** and **6** against MSSA; methicillin-sensitive *S. aureus*, MRSA; methicillin-resistant *S. aureus*, VSE; vancomycin-sensitive *E. faecium* and VRE.




Figure S2
Antibacterial activity of compound **6** and a physical mixture of vancomycin & compound **14** (7 μM each) against vancomycin-resistant Enterococci (VRE).




Figure S3.
Concentration dependent membrane depolarization studies of compounds **4** (A) and **6** (B) against MRSA.




Figure S4.
Concentration dependent membrane permeabilization studies of compounds **4** (A) and **6** (B) against MRSA.





Figure S5.
Percentage of intracellular potassium ion leakage caused by lipophilic cationic vancomycin derivatives (1-7) at 10 μ M against MRSA considering 100% K^+ leakage for valinomycin (10 μ M) as a positive control.

Table S1.Hemolysis and Cytotoxicity data of vancomycin and compounds **4** and **6**.



Compound	(Toxicity, μM)	
	Hemolytic activity (HC_{50})	Cytotoxicity (EC_{50})
Vancomycin	100	100
4	1000	100
6	100	100

III. Characterization (HPLC chromatograms, NMR and Mass spectra of vancomycin and new vancomycin analogues)


Vancomycin:




Vancomycin:





Compound 1:





Compound 1:




Compound 1:





Compound 2:





Compound 2:




Compound 2:





Compound **3**:





Compound 3:




Compound 3:





Compound **4**:




Compound 4:




Compound 4:




Compound 5:




Compound 5:




Compound 5:





Compound 6:




Compound 6:




Compound 6:





Compound 7:




Compound 7:



Compound 7:



Compound 13:



Compound 13:

